



Version: 4th March 2026

Country: United Kingdom

United Therapeutics: Methodological note for HCP/HCO disclosure [2025]

Data year: 2025

Year of publication: 2026

Contents

1	Definitions	4
1.1	Recipients.....	4
1.2	Kind of ToVs	4
2	Disclosure's Scope.....	4
2.1	Products concerned.....	4
2.2	Company concerned	4
2.3	Excluded ToVs.....	4
2.4	ToVs date	4
2.5	Direct ToVs	4
2.6	Indirect ToVs.....	5
2.7	Non-monetary ToVs	5
2.8	ToVs in case of partial attendances or cancellation and refund.....	5
2.9	Cross-border activities	5
2.10	R&D.....	5
2.11	Voluntary disclosure.....	5
3	Specific considerations	5
3.1	Country unique identifier.....	5
3.2	Self-incorporated HCP	5
3.3	Multi-year agreements	5
3.4	Country specificities.....	6
3.5	Quality Checks	6
4	Data protection legal basis	6
4.1	Consent collection	6
4.2	Legitimate interests	6
5	Form of disclosure.....	6
5.1	Date of publication.....	6
5.2	Disclosure platform.....	6
5.3	Disclosure language	6
6	Disclosure financial data	7
6.1	Currency.....	7
6.2	VAT included or excluded	7

6.3 Calculation rules.....	7
7 Additional Information.....	7

1 Definitions

1.1 Recipients

Recipients refer to UK-based healthcare professionals (HCPs) and healthcare organizations (HCOs) who received transfers of value (ToVs) from United Therapeutics during the reporting period. This includes individuals licensed to practice medicine, pharmacy, or allied health professions, and organizations involved in healthcare delivery or education.

1.2 Kind of ToVs

Transfers of value include consultancy fees, speaker fees, sponsorships for events, hospitality, donations, grants, fees for service, and non-monetary benefits such as educational materials and travel/accommodation related to professional activities.

2 Disclosure's Scope

2.1 Products concerned

Disclosures relate to all medicinal products marketed by United Therapeutics in the UK during the data year.

2.2 Company concerned

United Therapeutics Corporation, a pharmaceutical company operating in the UK. United Therapeutics is not a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

2.3 Excluded ToVs

Transfers of value related to non-promoted products, humanitarian donations not conditional on promotional activities, and ToVs outside of the UK jurisdiction are excluded.

2.4 ToVs date

The date of ToV is defined as the date the payment was made or the benefit was provided.

2.5 Direct ToVs

Direct ToVs are payments or benefits provided directly by United Therapeutics to HCPs or HCOs.

2.6 Indirect ToVs

Indirect ToVs are payments made via third parties on behalf of United Therapeutics where the ultimate beneficiary is an HCP or HCO.

2.7 Non-monetary ToVs

Includes provision of non-cash items such as educational materials or travel accommodations related to professional events.

2.8 ToVs in case of partial attendances or cancellation and refund

ToVs are disclosed net of any refunds or adjustments arising from cancellations or partial attendances.

2.9 Cross-border activities

Only ToVs related to activities conducted within the UK or to UK-based recipients are disclosed.

2.10 R&D

Payments linked to research and development activities, including clinical trial agreements and investigator grants, are disclosed where applicable.

2.11 Voluntary disclosure

United Therapeutics voluntarily discloses all relevant ToVs over and above regulatory requirements to promote transparency.

3 Specific considerations

3.1 Country unique identifier

Where available, unique identifiers assigned to HCPs or HCOs by UK regulatory or professional bodies are used to ensure accurate attribution.

3.2 Self-incorporated HCP

ToVs paid to HCPs operating as self-incorporated entities are disclosed under the entity name in accordance with ABPI guidelines.

3.3 Multi-year agreements

For payments under multi-year contracts, the disclosed amounts correspond to the actual payments made within the data year.

3.4 Country specificities

Disclosure methodology complies with UK-specific legal and regulatory requirements, including GDPR.

3.5 Quality Checks

Data is subjected to internal quality control reviews and validation processes to ensure accuracy and completeness.

4 Data protection legal basis

United Therapeutics fully supports the principles of transparency and abides by data privacy law.

4.1 Consent collection

HCPs and ORDMs are informed of how their personal data will be used in connection with ToV reporting and are provided with a Privacy Notice explaining the processing of their data.

4.2 Legitimate interests

The company will disclose any ToV on the lawful basis of pursuing its legitimate interests. The company's legitimate interests must be balanced against the interests and rights of the recipient. UT's Privacy Notice and the ABPI HCP-HCO Pre-Disclosure Fact Sheet have been distributed to affected individuals.

HCPs or ORDMs may exercise the right to object to individual disclosure, in which case, they must promptly inform United Therapeutics in writing at OpenPayments@unither.com. United Therapeutics will conduct Legitimate Interests balancing test and report the results to the individual. In cases where Privacy concerns outweigh Legitimate Interests, United Therapeutics will update the record to report the individual's ToV in aggregate form.

5 Form of disclosure

5.1 Date of publication

The disclosure is published each year in accordance with ABPI deadlines. 2025 data will be published on 30/06/2026.

5.2 Disclosure platform

Disclosures are made on the ABPI Disclosure UK platform: www.disclosureuk.org.uk.

5.3 Disclosure language

All disclosures are published in English.

6 Disclosure financial data

6.1 Currency

All monetary values are reported in GBP (British Pounds Sterling).

6.2 VAT included or excluded

Amounts are reported inclusive of VAT where applicable.

6.3 Calculation rules

Payments are reported at the gross contractual amount before any deduction.

7 Additional Information

No additional information to be added for 2025.